Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging resistance problems among respiratory tract pathogens.

P D Lister

    The American Journal of Managed Care
    |September 8, 2000
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.

    The Journal of antimicrobial chemotherapy·2001
    Same author

    Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
    Same author

    Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.

    Pharmacotherapy·2000
    Same author

    Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.

    The Journal of antimicrobial chemotherapy·1999
    Same author

    Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

    Antimicrobial agents and chemotherapy·1999
    Same author

    Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.

    Antimicrobial agents and chemotherapy·1999

    Antibiotic resistance in respiratory infections is rising, impacting treatment strategies. New approaches are needed to manage bacterial resistance effectively and ensure optimal patient outcomes.

    Area of Science:

    • Infectious Diseases
    • Microbiology
    • Pharmacology

    Background:

    • Respiratory tract infections are the leading cause of antibiotic prescriptions in the U.S.
    • Significant shifts in pathogen spectrum and increasing bacterial resistance are altering infection management.
    • Community-acquired pneumonia epidemiology has evolved, marked by greater pathogen diversity and higher mortality.

    Purpose of the Study:

    • To review the current landscape of antibiotic resistance in respiratory pathogens.
    • To highlight the challenges posed by emerging resistance patterns to common antibiotics.
    • To discuss the implications for current and future treatment strategies for respiratory tract infections.

    Main Methods:

    • Literature review of epidemiological data on respiratory pathogens.

    Related Experiment Videos

  • Analysis of antibiotic resistance trends, particularly for beta-lactams and fluoroquinolones.
  • Examination of resistance patterns in key pathogens like Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus.

    • Main Results:

    • High rates of resistance observed: over 33% of Haemophilus influenzae and nearly all Moraxella catarrhalis are beta-lactam resistant.
    • Over 40% of Streptococcus pneumoniae isolates show penicillin resistance; up to 50% of Staphylococcus aureus isolates are methicillin-resistant.
    • Fluoroquinolone resistance is low in many respiratory pathogens but emerging rapidly in Staphylococcus aureus, often linked to methicillin resistance.

    Conclusions:

    • Current treatment of respiratory tract infections requires broad-spectrum empiric therapy considering bacterial resistance.
    • New antimicrobial options and strategies emphasizing effective use and optimal dosing are crucial.
    • The growing problem of antibiotic resistance necessitates changes in treatment approaches for all respiratory tract infections.